| Ident. | Authors (with country if any) | Title |
|---|
| 000107 (2011) |
Karl Kieburtz [États-Unis] | Twice‐daily, low‐dose pramipexole in early Parkinson's disease: A randomized, placebo‐controlled trial |
| 000265 (2011) |
James A. Miller [États-Unis] ; Briana R. Trout [États-Unis] ; Kelly A. Sullivan [États-Unis] ; Russell A. Bialecki [États-Unis] ; Ruth A. Roberts [Royaume-Uni] ; Ronald B. Tjalkens [États-Unis] | Low‐dose 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine causes inflammatory activation of astrocytes in nuclear factor‐κB reporter mice prior to loss of dopaminergic neurons |
| 000339 (2011) |
Jee-Young Lee [Corée du Sud] ; Jinwhan Cho [Corée du Sud] ; Eun-Kyung Lee [Corée du Sud] ; Sung-Sup Park [Corée du Sud] ; Beom S. Jeon [Corée du Sud] | Differential genetic susceptibility in diphasic and peak‐dose dyskinesias in Parkinson's disease |
| 000379 (2011) |
Robert D. Altman [Canada] ; Anthony E. Lang [Canada] ; Ronald B. Postuma [Canada] | Caffeine in Parkinson's disease: A pilot open‐label, dose‐escalation study |
| 000500 (2010) |
Tanya Simuni [États-Unis] ; Emily Borushko [États-Unis] ; Michael J. Avram [États-Unis] ; Scott Miskevics [États-Unis] ; Audrey Martel [États-Unis] ; C. Zadikoff [États-Unis] ; Aleksandar Videnovic [États-Unis] ; Frances M. Weaver [États-Unis] ; Karen Williams [États-Unis] ; D. James Surmeier [États-Unis] | Tolerability of isradipine in early Parkinson's disease: A pilot dose escalation study |
| 000532 (2010) |
Claire L. Tomlinson [Royaume-Uni] ; Rebecca Stowe [Royaume-Uni] ; Smitaa Patel [Royaume-Uni] ; Caroline Rick [Royaume-Uni] ; Richard Gray [Royaume-Uni] ; Carl E. Clarke [Royaume-Uni] | Systematic review of levodopa dose equivalency reporting in Parkinson's disease |
| 000611 (2010) |
Olivier Rascol [France] ; Jean-Philippe Azulay [France] ; Olivier Blin [France] ; Anne-Marie Bonnet [France] ; Christine Brefel-Courbon [France] ; Pierre Césaro [France] ; Philippe Damier [France] ; Bérengère Debilly [France] ; Frank Durif [France] ; Monique Galitzky [France] ; Jean-Marie Grouin [France] ; Sylvie Pennaforte [France] ; Gabriel Villafane [France] ; Sadek Yaici [France] ; Yves Agid [France] | Orodispersible sublingual piribedil to abort OFF episodes: A single dose placebo‐controlled, randomized, double‐blind, cross‐over study |
| 000694 (2010) |
Yutaka Naito [Japon] ; Ko Matsuo [Japon] ; Yasumasa Kokubo [Japon] ; Yugo Narita [Japon] ; Hidekazu Tomimoto [Japon] | Higher‐dose glutathione therapy for Parkinson's disease in Japan: Is it really safe? |
| 000959 (2009) |
Addy [États-Unis] ; Assaid [États-Unis] ; Hreniuk [États-Unis] ; Stroh [États-Unis] ; Xu [États-Unis] ; Herring [États-Unis] ; Ellenbogen [États-Unis] ; Jinnah [États-Unis] ; Kirby [États-Unis] ; Leibowitz [États-Unis] ; Stewart [États-Unis] ; Tarsy [États-Unis] ; Tetrud [États-Unis] ; Stoch [États-Unis] ; Gottesdiener [États-Unis] ; Wagner [États-Unis] | Single‐Dose Administration of MK‐0657, an NR2B‐Selective NMDA Antagonist, Does Not Result in Clinically Meaningful Improvement in Motor Function in Patients With Moderate Parkinson's Disease |
| 000C72 (2008) |
G. Linazasoro [Espagne] ; J. Kulisevsky [Espagne] ; B. Hernández [Espagne] | Should levodopa dose be reduced when switched to stalevo? |
| 001213 (2006) |
Angelo Antonini [Italie] ; Silvana Tesei [Italie] ; Anna Zecchinelli [Italie] ; Paolo Barone [Italie] ; Danilo De Gaspari [Italie] ; Margherita Canesi [Italie] ; Giorgio Sacilotto [Italie] ; Nicoletta Meucci [Italie] ; Claudio Mariani [Italie] ; Gianni Pezzoli [Italie] | Randomized study of sertraline and low‐dose amitriptyline in patients with Parkinson's disease and depression: Effect on quality of life |
| 001249 (2006) |
Joseph H. Friedman [États-Unis] ; Robert M. Berman [États-Unis] ; Christopher G. Goetz [États-Unis] ; Stewart A. Factor [États-Unis] ; William G. Ondo [États-Unis] ; Joanne Wojcieszek [États-Unis] ; William H. Carson [États-Unis] ; Ronald N. Marcus [États-Unis] | Open‐label flexible‐dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease |
| 001309 (2006) |
P. Odin [Allemagne] ; C. Oehlwein [Allemagne] ; A. Storch [Allemagne] ; U. Polzer [Allemagne] ; G. Werner [Allemagne] ; R. Renner [Allemagne] ; M. Shing [Allemagne] ; A. Ludolph [Allemagne] ; P. Schüler [Allemagne] | Efficacy and safety of high‐dose cabergoline in Parkinson's disease |
| 001516 (2005) |
Regina Katzenschlager [Royaume-Uni, Autriche] ; Andrew Hughes [Australie] ; Andrew Evans [Royaume-Uni] ; Alice J. Manson [Royaume-Uni] ; Marion Hoffman [Australie] ; Lesley Swinn [Royaume-Uni] ; Hilary Watt [Royaume-Uni] ; Kailash Bhatia [Royaume-Uni] ; Niall Quinn [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni] | Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: A prospective study using single‐dose challenges |
| 001778 (2003) |
Lance A. Smith [Royaume-Uni] ; Michael J. Jackson [Royaume-Uni] ; Matthew J. Hansard [Royaume-Uni] ; Eleni Maratos [Royaume-Uni] ; Peter Jenner [Royaume-Uni] | Effect of pulsatile administration of levodopa on dyskinesia induction in drug‐naïve MPTP‐treated common marmosets: Effect of dose, frequency of administration, and brain exposure |
| 001D24 (1999) |
Judit Mally [Hongrie] ; T. W. Stone [Royaume-Uni] | Therapeutic and “dose‐dependent” effect of repetitive microelectroshock induced by transcranial magnetic stimulation in Parkinson's disease |
| 001D43 (1999) |
Anette Schrag [Royaume-Uni] ; Ludwig Schelosky [Allemagne] ; Udo Scholz [Allemagne] ; Werner Poewe [Autriche] | Reduction of parkinsonian signs in patients with Parkinson's disease by dopaminergic versus anticholinergic single‐dose challenges |
| 001D87 (1999) |
Paul Krack ; Pierre Pollak [France] ; Patricia Limousin ; Abdelhamid Benazzouz ; Gu Nther Deuschl ; Alim-Louis Benabid [France] | From off-period dystonia to peak-dose chorea |
| 002129 (1996) |
J. Boas [Danemark] ; J. Worm-Petersen [Danemark] ; E. Dupont [Danemark] ; B. Mikkelsen [Danemark] ; L. Wermuth [Danemark] | The levodopa dose‐sparing capacity of pergolide compared with that of bromocriptine in an open‐label, crossover study |
| 002134 (1996) |
M. Gerlach [Allemagne] ; W. Kuhn ; Th. Müller ; P. Klotz ; H. Przuntek | Sustained-release of levodopa: single dose study of a new formulation |
| 002154 (1996) |
Kl Rost [Allemagne] ; I. Roots [Allemagne] | Nonlinear kinetics after high-dose omeprazole caused by saturation of genetically variable CYP2C19 |
